The t(4;11)(q21;q23) translocation is associated with high-risk infant pro-B-cell acute lymphoblastic leukemia 40 and arises prenatally during embryonic/fetal hematopoiesis. The developmental/pathogenic contribution of 41 the t(4;11)-resulting MLL-AF4 (MA4) and AF4-MLL (A4M) fusions remains unclear; MA4 is always expressed 42 in t(4;11)+ B-cell acute lymphoblastic leukemia patients, but the reciprocal fusion A4M is expressed in only 43 half of the patients. Because prenatal leukemogenesis manifests as impaired early hematopoietic 44 differentiation, we took advantage of well-established human embryonic stem cell-based hematopoietic 45 differentiation models to study whether the A4M fusion cooperates with MA4 during early human 46 hematopoietic development. Co-expression of A4M and MA4 strongly promoted the emergence of hemato-47 endothelial precursors, both endothelial-and hemogenic-primed. Double fusion-expressing hemato-48 endothelial precursors specified into significantly higher numbers of both hematopoietic and endothelial-49 committed cells, irrespective of the differentiation protocol used and without hijacking survival/proliferation. 50
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Functional analysis of differentially expressed genes and differentially enriched H3K79me3 genomic regions 51
by RNA-seq and H3K79me3 ChIP-seq, respectively, confirmed a hematopoietic/endothelial cell 52 differentiation signature in double fusion-expressing hemato-endothelial precursors. Importantly, ChIP-seq 53 analysis revealed a significant enrichment of H3K79 methylated regions specifically associated with HOX-A 54
cluster genes in double fusion-expressing differentiating hematopoietic cells. Overall, these results establish 55 a functional and molecular cooperation between MA4 and A4M fusions during human hematopoietic 56 continuum HEP-to-blood transition, MA4-expressing hEBs display an enhanced HEP production coupled to 228 an impaired blood output (EB day 20, Fig S2A) and clonogenic potential (EB day 15, Fig 2B) . We confirmed 229 stable expression of ectopic MA4 and A4M upon EB differentiation, supporting the link between genotype 230 and phenotype (Fig2C) . 231
232
We also investigated hematopoietic differentiation using the OP9 differentiation system (Fig3A,B), and by 233 plating FACS-sorted HEPs in either hematopoietic liquid culture (Fig3C) or onto MS5 feeders (Fig3D). After 234 10 days on OP9 stroma, double fusion-expressing hESCs yielded a 10-fold higher number of CD45+ 235 hematopoietic cells than did single fusion-expressing hESCs (Fig3B). Moreover, when HEPs were FACS-236 sorted from day 9 OP9 co-cultures and allowed to differentiate into CD45+ blood cells, the yield of CD45+ 237 cells was up to 60-fold higher in double fusion-expressing HEPs than in single fusion-expressing HEPs. 238 (Fig3C, D) . Encouraged by these results, we next investigated whether ectopic expression of both A4M and 239 MA4 confers in vivo engraftment capacity to hESC-derived hematopoietic derivatives. To do this, we 240 transplanted 5×10 5 hESC hematopoietic derivatives from each genotype into myeloablated NSG mice 4, 43, 47 , 241 finding that, despite regulating hematopoietic development in vitro, double fusion-expression did not confer 242 in vivo engraftment to hESC hematopoietic derivatives (Fig2D) . 243
244
The increased hematopoietic output of double fusion-expressing hESCs might be the consequence of 245 transgene-mediated proliferation/survival of the emerging HEPs or CD45+ cells. To address this, we 246 analyzed cell cycle distribution (FigS2B) and apoptosis (FigS2C) within both HEPs and the CD45+ cell 247 population. No differences in the proportion of either cycling HEPs or CD45+ cells were detected between 248 genotypes (25-36% for HEPs and 35-41% for CD45+ cells; FigS2B). Apoptotic levels were similarly low 249 between the different genotypes of HEPs (6-8%) To identify patterns of gene expression that might molecularly explain the functional co-operation between 282 A4M and MA4 in hematopoietic specification, we performed RNA-seq analysis on FACS-purified EV-, MA4, 283 A4M-and double fusion-expressing HEPs from day 15 hEBs. Fig6A shows a heatmap representation of the 284 hierarchical clustering of the 335 genes differentially expressed between the four genotypes (TableS2). 285
There is a clear transcriptomic transition towards a hematopoietic/endothelial gene signature from EV-HEPs 286 to double-fusion-expressing HEPs. Single fusion-expressing HEPs clustered interspersed between EV and 287 double-fusion HEPs. The biological functions affected by genes differentially expressed in MA4-, A4M-and 288 double fusion-expressing HEPs relative to EV were classified by IPA software 47, 52 and among the top 289 significant enriched functional categories were "hematological system development and function", "cancer" 290 and "hematological disease" (Fig6B). Statistical (-log(p-value)) power shows distant effects of MA4 and A4M; 291 however, co-expression of both fusions seems to establish a molecular balance/developmental cooperation 292 in promoting blood-endothelial specification from hPSCs. Strikingly, biofunctions specifically associated to 293 hematological lymphoid malignancies (not with non-hematological cancer) were predicted to be activated 294 (positive z-score) exclusively in double fusion-expressing HEPs, further suggesting a molecular cooperation 295 between MA4 and A4M in development and infant leukemia. (Fig6C) . 296
13
The C-terminal-partners of MLL fusions normally interact with the histone methyltransferase DOT1L, which 297 is the sole histone methyltransferase catalyzing histone 3 lysine 79 (H3K79) methylation, a chromatin 298 modification widely associated with the dysregulated expression of HOX-A cluster genes in MLL leukemias 299 13, 53 . We thus performed genome-wide ChIP-seq analysis of the H3K79 trimethylation (H3K79me3) profiles 300 in control, MA4-, A4M-and double fusion-expressing hESC-derived blood derivatives (Fig7, S3A, TableS3) . 301
In line with the RNA-seq data, functional analysis of the differential H3K79me3 peaks specific for double 302 fusion-expressing cells revealed significant GO functional categories associated with "definitive 303 hematopoiesis", "myeloid and erythroid differentiation/homeostasis" and "endothelial cell development" 304 protocol, reveal that 45% of t(4;11)+ patients express the A4M fusion, and that HOX-A cluster genes are 319 exclusively expressed in this AF4-MLL-expressing subgroup of t(4;11)+ patients, who in fact display a 320 significant more favorable clinical outcome 19 . 321
322

DISCUSSION
324
From an etiological and pathogenesis standpoint, infant cancer is distinct to adult cancer and should be 325 studied as a developmental disease 4, 7, 16 . A biologically and clinically intriguing infant cancer is the t(4;11)+ 326 B-ALL, which is associated with a dismal outcome 4, 21, 23 . Evidence in support of its prenatal origin comes from 327 studies in monozygotic twins and archived blood spots, providing compelling evidence of a single prenatal 328 cell as the origin for t(4;11) 5 , and also from recent genome-wide studies demonstrating that this infant 329 leukemia has one of the lowest frequencies of somatic mutations of any sequenced cancer 55 . The stable 330 genome of these patients suggests that in infant developmental cancer, one "big-hit" might be sufficient for 331 overt disease, supporting a key contribution of the prenatal cell-of-origin during a critical developmental 332 window of stem cell vulnerability in leukemogenesis. However, despite its aggressiveness and short latency, 333 our current understanding about its etiology, pathogenesis and cellular origin is still limited 2, 4, 16, 52 . Importantly, 334 a recently developed xenograft model which represents the most bona fide model for t(4;11)+ B-ALL so far, 335 has revealed the instructive role of MLL-Af4 in cord blood-derived CD34+ cells 14 . 336
337
Studies using primary cells from t(4;11)+ B-ALL patients are incapable of addressing the developmental 338 genesis of the hematopoietic system. Recent data suggest that fetal liver lymphoid-primed multipotent 339 progenitor may provide the developmental prerequisites for the initiation of t(4;11)+/MLL-AF4 infant 340 leukemia 56 . Because leukemogenesis manifests as a blockage or altered cell differentiation, the 341 hematopoietic differentiation of hESCs may represent a promising in vitro model to study the onset of 342 hematopoiesis and the earliest events leading to the specification of the hematopoietic cells 36 . Previous 343 studies have addressed the oncogenic role of leukemic fusion genes in hESC-derived hematopoiesis 57, 5859 . 344
We previously explored the developmental impact of the pre-natal fusion MA4 in hESC hemato-endothelial 345 development 10 , and found that MA4 expression promotes the emergence of endothelial-primed HEPs and 346 further endothelial commitment, but hijacks the specification of hemogenic-primed HEPs, impairing 347 hematopoietic output 10 . 348
349
The functional and molecular contribution of the reciprocal fusion genes resulting from the derivative 350 translocated chromosomes remains obscure in cancer 18, 60 . The MA4 fusion is always expressed in t(4;11)+B-351 ALL patients, whereas the reciprocal fusion A4M is expressed in only 45-50% of the patients 18, 60, 19, 20 . Here, 352
we took advantage of well-established hESC-based differentiation systems to study whether the A4M fusion 353 cooperates with MA4 during early human hematopoietic and endothelial development. Co-expression of A4M 354 and MA4 strongly promoted the emergence of HEPs, both endothelial-primed and hemogenic-primed. 355
Moreover, the double fusion-expressing HEPs specified into significantly higher numbers of both 356 hematopoietic and endothelial cells, irrespective of the in vitro differentiation protocol used and without 357 affecting survival or proliferation, indicating a functional (developmental) co-operation between MA4 and A4M 358 fusions during human hematopoietic development. This notion was confirmed by genome-wide 359 transcriptomic analysis of differentiating HEPs. These developmental biology studies support previous 360 evidence suggesting that A4M contributes to the pathobiology of t(4;11)+ B-ALL. Accordingly, Bursen 11 361 reported that A4M-transduced murine hematopoietic stem cells (HSCs) developed pro-B-ALL, whereas co-362 transduction with MA4 and A4M resulted in mixed lineage leukemia. Moreover, studies from Milne's 363 laboratory demonstrated that RUNX1 is directly activated by MA4 and the RUNX1 protein interacts with the 364 A4M protein, suggesting a mechanism of co-operation between the two fusion genes at the molecular level 25 . 365
366
In the embryo, definitive hematopoiesis cannot occur in the absence of endothelial cell development. 367
Definitive HSCs in both mouse and human emerge from the hemogenic endothelium by a process known as 368 endothelial-to-hematopoietic transition 61 . Hematopoietic differentiation of hESCs occurs through the 369 generation of HEPs, from which then originate both endothelial and hematopoietic cells. Here, co-expression 370 of A4M and MA4 in HEPs concomitantly promoted endothelial and hematopoietic commitment rather than 371 skewing the hemato-endothelial commitment in favor of one lineage over the other. This finding is important 372 because beyond their pathogenic role in acute leukemias, the MLL gene is implicated in endothelial cell 373 maturation, and endothelial dysfunction was recently linked to disease outcome in childhood leukemias 31, 32 . 374
Furthermore, other leukemia fusion oncogenes as well as lymphoma-specific genetic aberrations have been 375 found in endothelial cells from chronic myeloid leukemia and B-cell lymphoma patients 10, 43, 44 , suggesting that 376 endothelial cells may be part of the neoplastic clone. Also, BM-derived mesenchymal stem cells (BM-MSCs) 377 from infant t(4;11)+ B-cell ALL were recently found to harbor and express the t(4;11) translocation 33 . The 378 existence of a common embryonic precursor for MSCs and endothelial cells has been recently demonstrated 379 by hESC-directed differentiation 10, 45 . The finding of such a common embryonic precursor, and the presence 380 of t(4;11) in both leukemic blasts and BM-MSCs of infant patients, suggests that the t(4;11) translocation 381 arises and has a developmental impact on early pre-hematopoietic precursors. As a technical caveat, it is 382 important to emphasize that MA4 and A4M were sequentially transduced to allow for antibiotic selection and 383 homogeneously-transduced hESC cultures. However, in double-fusion-expressing differentiating blood cells, 384 MA4 was never individually expressed in the absence of A4M. When hematopoietic differentiation of hESCs 385 was induced by EB formation both fusions were readily co-expressed, ruling out a biased functional 386 phenotype driven by the sequential expression of each transgene in distinct developmental windows. 387
389
Mechanistically, a putative function of A4M is to activate chromatin, rendering a chromatin landscape similar 390
to that during stem cell development. It is currently unknown how A4M is able to reprogram chromatin, but it 391 does contain the SET domain disrupted from its "specification domain", the N-terminal portion of MLL, whichbinds to MEN1 and LEDGF, shaping the gene targeting module of the MLL gene. When A4M is expressed, 393 the N-terminal portion is substituted by the AF4 N-terminus, which is the crucial domain (AF4N) that binds to 394 and strongly activates RNA polymerase II (RNAP II) for transcriptional elongation. Overexpression of either 395 AF4, AF4N or the fusion protein A4M induces robust RNAP II-dependent gene transcription by overwriting 396 the elongation control process in a dominant fashion [62] [63] [64] . Since gene transcription per se and in particular 397 "sterile" transcription is a powerful mechanism for chromatin activation, A4M could potentiate MA4 to skew 398 normal and leukemic hematopoietic cell fate decisions. This also explains why MA4 has a more prominent 399 role in the disease than the reciprocal A4M. If A4M functioned to initiate this process only by itself, then it 400 would become obsolete after fulfilling the "chromatin opening job". However, transcription factors like MA4, 401 
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SUPPLEMENTARY LEGENDS AND METHODS
Chromatin immunoprecipitation Sequencing
One million day 15 hematopoietic differentiating hEB-derived cells were subjected to Chromatin
Immunoprecipitation (ChIP) as described 1 . Briefly, formaldehyde crosslinked cell extracts were sonicated using a Bioruptor (Diagenode) with a 0.5-min interval protocol to obtain DNA fragments of 200-500 bp. The chromatin fraction was divided into three parts and incubated overnight with 2 g of anti-H3K4me3, anti-H3K79me3, or anti-H3 antibodies (Abcam) in RIPA buffer, and precipitated with protein A/G-Sepharose (Amersham). Cross-linkage of the co-precipitated DNA-protein complexes was reversed, and the DNA was sequenced at the CRG-CNAG Genomics Facility. Paired-end 50 bp ChIPseq data reads were generated using a HiSeq 2500 Illumina sequencer. Alignment and peak detection was performed using the ENCODE (phase-3) histone ChIP-seq pipeline specifications. Reads were aligned to the human reference genome (assembly hg19) using BWA 2 , removing all reads with a quality score <30. Peaks were called using MACS2 3 and whole cell extract samples as background samples.
Differential analysis of histone mark peaks between experimental groups and the EV control group was performed using DiffBind 4 , with a False Discovery Rate (FDR) cut-off of 0.1. Peaks annotation and Gene Ontology (GO) enrichment were analyzed with ChIP-Enrich package in R 4 , using an FDR threshold of 0.1. ChIP-Seq data is deposited and available at Gene Expression Omnibus (GEO, accession number GSE111263).
Low-input RNA-seq and bulk RNA-seq on t(4;11)+B-ALL patients
For low-input RNAseq, 50 HEPs were FACS-purified from day 15 EBs into individual wells of a 96-well PCR plate containing lysis buffer (0.2% Triton-X100 and 2.3 U of SUPERase-In RNase Inhibitor; Ambion). Three independent replicates (50 cells/replicate) per condition were analyzed. RNA/cDNA was obtained and amplified as per the SMARTSEQ2 protocol 5, 6 . Libraries were prepared for sequencing using the Illumina Nextera XT DNA preparation kit. RNA-seq data was generated using a 50 single-end sequencing protocol. Pooled libraries were sequenced on the Illumina HiSeq 4000 platform. Reads were mapped to the human genome (Ensembl 81) and the ERCC sequences using STAR (version 2.4.2a) with default parameters. HTseq-count 7 was used to count the number of reads mapped to each gene with -s no (non-strand specific mode). Data were normalized for sequencing depth using the size factor from the DESeq2 package (version 1.12.2) 8 . Low-input RNA-seq data is deposited and available at GEO (GSE118947).
Bulk RNA-seq data on t(4;11)+ B-ALL patients was generated on the Illumina HiSeq 2500 platform using a 76 paired-end sequencing protocol and aligned to the human reference genome (hg19) using GAGCCCTACAAGACAGCAAAAGGTGATGAGCTGTCTAGTCGAATACAGAACATGTTGGGAAAC  TACGAAGAAGTGAAGGAGTTCCTTAGTACTAAGTCTCACACTCATCGCCTGGATGCTTCTGAAA  ATAGGTTGGGAAAGCCGAAATATCCTTTAATTCCTGACAAAGGGAGCAGCATTCCATCCAGCT  CCTTCCACACTAGTGTCCACCACCAGTCCATTCACACTCCTGCGTCTGGACCACTTTCTGTTGG  CAACATTAGCCACAATCCAAAGATGGCGCAGCCAAGAACTGAACCAATGCCAAGTCTCCATGC  CAAAAGCTGCGGCCCACCGGACAGCCAGCACCTGACCCAGGATCGCCTTGGTCAGGAGGGG  TTCGGCTCTAGTCATCACAAGAAAGGTGACCGAAGAGCTGACGGAGACCACTGTGCTTCGGT  GACAGATTCGGCTCCAGAGAGGGAGCTTTCTCCCTTAATCTCTTTGCCTTCCCCAGTTCCCCC  TTTGTCACCTATACATTCCAACCAGCAAACTCTTCCCCGGACGCAAGGAAGCAGCAAGGTTCA  TGGCAGCAGCAATAACAGTAAAGGCTATTGCCCAGCCAAATCTCCCAAGGACCTAGCAGTGAA  AGTCCATGATAAAGAGACCCCTCAAGACAGTTTGGTGGCCCCTGCCCAGCCGCCTTCTCAGAC  ATTTCCACCTCCCTCCCTCCCCTCAAAAAGTGTTGCAATGCAGCAGAAGCCCACGGCTTATGT  CCGGCCCATGGATGGTCAAGATCAGGCCCCTAGTGAATCCCCTGAACTGAAACCACTGCCGG  AGGACTATCGACAGCAGACCTTTGAAAAAACAGACTTGAAAGTGCCTGCCAAAGCCAAGCTCA  CCAAACTGAAGATGCCTTCTCAGTCAGTTGAGGAGGATTGTGAAGCAGAAAATGTGTGGGAGA  TGGGAGGCTTAGGAATCTTGACTTCTGTTCCTATAACACCCAGGGTGGTTTGCTTTCTCTGTGC  CAGTAGTGGGCATGTAGAGTTTGTGTATTGCCAAGTCTGTTGTGAGCCCTTCCACAAGTTTTGT  TTAGAGGAGAACGAGCGCCCTCTGGAGGACCAGCTGGAAAATTGGTGTTGTCGTCGTTGCAA  ATTCTGTCACGTTTGTGGAAGGCAACATCAGGCTACAAAGCAGCTGCTGGAGTGTAATAAGTG  CCGAAACAGCTATCACCCTGAGTGCCTGGGACCAAACTACCCCACCAAACCCACAAAGAAGAA  GAAAGTCTGGATCTGTACCAAGTGTGTTCGCTGTAAGAGCTGTGGATCCACAACTCCAGGCAA  AGGGTGGGATGCACAGTGGTCTCATGATTTCTCACTGTGTCATGATTGCGCCAAGCTCTTTGC  TAAAGGAAACTTCTGCCCTCTCTGTGACAAATGTTATGATGATGATGACTATGAGAGTAAGATG  ATGCAATGTGGAAAGTGTGATCGCTGGGTCCATTCCAAATGTGAGAATCTTTCAGGTACAGAA  GATGAGATGTATGAGATTCTATCTAATCTGCCAGAAAGTGTGGCCTACACTTGTGTGAACTGTA  CTGAGCGGCACCCTGCAGAGTGGCGACTGGCCCTTGAAAAAGAGCTGCAGATTTCTCTGAAG  CAAGTTCTGACAGCTTTGTTGAATTCTCGGACTACCAGCCATTTGCTACGCTACCGGCAGGCT  GCCAAGCCTCCAGACTTAAATCCCGAGACAGAGGAGAGTATACCTTCCCGCAGCTCCCCCGA  AGGACCTGATCCACCAGTTCTTACTGAGGTCAGCAAACAGGATGATCAGCAGCCTTTAGATCT  AGAAGGAGTCAAGAGGAAGATGGACCAAGGGAATTACACATCTGTGTTGGAGTTCAGTGATGA  TATTGTGAAGATCATTCAAGCAGCCATTAATTCAGATGGAGGACAGCCAGAAATTAAAAAAGCC  AACAGCATGGTCAAGTCCTTCTTCATTCGGCAAATGGAACGTGTTTTTCCATGGTTCAGTGTCA  AAAAGTCCAGGTTTTGGGAGCCAAATAAAGTATCAAGCAACAGTGGGATGTTACCAAACGCAG  TGCTTCCACCTTCACTTGACCATAATTATGCTCAGTGGCAGGAGCGAGAGGAAAACAGCCACA  CTGAGCAGCCTCCTTTAATGAAGAAAATCATTCCAGCTCCCAAACCCAAAGGTCCTGGAGAAC  CAGACTCACCAACTCCTCTGCATCCTCCTACACCACCAATTTTGAGTACTGATAGGAGTCGAGA 
